Overview
The von Willebrand factor antigen test is a laboratory investigation used to assess the level of von Willebrand factor, a key glycoprotein involved in hemostasis and the coagulation system. vWF plays a crucial role in platelet adhesion at sites of vascular injury and acts as a carrier protein for factor VIII, protecting it from degradation. It is synthesized by megakaryocytes and vascular endothelial cells and circulates as an acute-phase reactant. Deficiency or dysfunction of vWF leads to impaired clot formation and increased bleeding tendency.
Symptoms
Abnormal vWF levels are commonly associated with bleeding manifestations that may range from mild to severe. Patients may present with easy bruising, recurrent nosebleeds, heavy menstrual bleeding, hematemesis, hematuria, or hemoptysis. In many cases, symptoms are lifelong and may worsen during surgery, trauma, or childbirth. Some individuals remain asymptomatic until exposed to a hemostatic challenge.
Causes
Reduced levels or defective function of vWF result in von Willebrand disease, which may be inherited or acquired. Inherited forms include quantitative deficiency, qualitative defect, or complete absence of vWF. Acquired reduction may be seen in conditions such as severe liver disease or hypothyroidism.
Increased vWF levels occur because it is an acute-phase reactant and may rise temporarily in infections, chronic inflammation, trauma, pregnancy, estrogen therapy, malignancy, renal disease, intravascular hemolysis, connective tissue disorders, cardiovascular disease, and thrombotic thrombocytopenic purpura. Blood group also influences vWF levels, with lower levels commonly seen in individuals with blood group O.
Risk Factors
Family history of bleeding disorders is a major risk factor for von Willebrand disease. Other risk factors include liver disease, renal disease, hypothyroidism, chronic inflammatory states, pregnancy, estrogen use, and cardiovascular conditions. Surgical procedures, trauma, and invasive interventions increase the risk of bleeding in individuals with low or dysfunctional vWF. Blood group O individuals naturally have lower baseline vWF levels compared to other blood groups.
Prevention
Early identification of vWF abnormalities through appropriate testing helps prevent bleeding complications. Patients with known von Willebrand disease should avoid unnecessary trauma and inform healthcare providers before surgical or dental procedures. Regular monitoring, especially during pregnancy or before surgery, reduces risk. Appropriate treatment with vWF concentrates and antifibrinolytic agents, along with management of underlying conditions, helps prevent excessive bleeding and improves clinical outcomes.
